Tailored Treatment of Functional Dyspepsia With Nortriptyline: A Multicenter, Double-Blind, Placebo-Controlled Trial
Clinical Gastroenterology and Hepatology · 2026-08 · 24 (8) · 2273-2285
DOI: 10.1016/j.cgh.2026.01.013 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Clinical Gastroenterology and Hepatology, 2026-08. Verfasst von Daan H C A Bosch und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Maastricht University Medical Center+, Maastricht, the Netherlands; NUTRIM: School of Nutrition and Tr…. Hauptthemen laut MEDLINE: Antidepressive Agents, Tricyclic, Dyspepsia, Nortriptyline. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Netherlands Organisation for Health Research and Development.
Abstract (Originalsprache)
BACKGROUND & AIMS: Low-dose tricyclic antidepressants may be effective for patients with functional dyspepsia (FD), although high-quality randomized controlled trials (RCTs) are limited. We aimed to investigate the efficacy of nortriptyline in an escalating low-dose regimen vs placebo in participants with FD following a genotype-guided pre-selection based on cytochrome P450 2D6 (CYP2D6), the primary enzyme responsible for nortriptyline metabolism. METHODS: We conducted a multicenter, RCT of patients with FD in primary, secondary, and tertiary care. Sixty-nine participants were randomly assigned to nortriptyline (weeks 1-2: 10 mg; weeks 3-4: 25 mg; weeks 5-12: 50 mg) vs placebo for a 12-week treatment. The primary outcome was clinical response based on a decrease in FD symptoms of at least 30% compared with baseline, in 50% of the last 10 weeks of the treatment period. RESULTS: The primary outcome showed no significant difference in response for nortriptyline compared with placebo (45% vs 58%; odds ratio [OR], 0.574; 95% confidence interval [CI], 0.211-1.560; P = .276). There was no significant difference in adverse events between the nortriptyline and placebo group. Nortriptyline plasma levels were significantly higher in responders compared with non-responders (13.0 μg/L; interquartile range [IQR], 12.0-16.0 vs 9.0 μg/L; IQR, 8.0-10.5; P = .003). The belief to have received nortriptyline showed a higher response rate than the belief to have received placebo (77% vs 36%; OR, 11.439; 95% CI, 2.138-61.201; P = .004). CONCLUSIONS: Nortriptyline was not more effective than placebo in reducing FD symptoms in participants pre-selected based on CYP2D6 genotype, although a biological effect of nortriptyline could not be ruled out. However, effects related to participants' belief appeared to be stronger. CLINICALTRIALS: gov, Number, NCT03652571.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, Maastricht University Medical Center+, Maastricht, the Netherlands; NUTRIM: School of Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht,…
- CAPHRI: Care and Public Health Research Institute, Maastricht University, Maastricht, the Netherlands; Department of Methodology and Statistics, Maastricht University, Maastricht, the Netherlands.
- CAPHRI: Care and Public Health Research Institute, Maastricht University, Maastricht, the Netherlands; Department of Family Medicine, Maastricht University, Maastricht, the Netherlands.
- Department of General Practice and Elderly Care Medicine, University Medical Center Utrecht, Utrecht, the Netherlands.
- Department of Pharmacotherapy, Epidemiology, and Economics, University of Groningen, Groningen, the Netherlands.
- Department of Gastroenterology and Hepatology, Jeroen Bosch Hospital, 's-Hertogenbosch, the Netherlands.
Förderung
- Netherlands Organisation for Health Research and Development
Zitieren
APA
Bosch, D. H. C. A., Beckers, A. B., Snijkers, J. T. W., Bosman, M. H. M. A., Winkens, B., Muris, J. W. M., de Wit, N., Brouwers, J. R. B. J., van Hee, K., Clemens, C. H. M., Haarhuis, B. J. T., Witteman, B. J. M., Masclee, A. A. M., & Keszthelyi, D. (2026). Tailored Treatment of Functional Dyspepsia With Nortriptyline: A Multicenter, Double-Blind, Placebo-Controlled Trial. Clinical Gastroenterology and Hepatology, 24(8), 2273-2285. https://doi.org/10.1016/j.cgh.2026.01.013
Vancouver
Bosch DHCA, Beckers AB, Snijkers JTW, Bosman MHMA, Winkens B, Muris JWM, et al. Tailored Treatment of Functional Dyspepsia With Nortriptyline: A Multicenter, Double-Blind, Placebo-Controlled Trial. Clinical Gastroenterology and Hepatology. 2026;24(8):2273-2285. doi:10.1016/j.cgh.2026.01.013
BibTeX
@article{Bosch2026,
author = {Bosch, Daan H C A and Beckers, Abraham B and Snijkers, Johanna T W and Bosman, Michelle H M A and Winkens, Bjorn and Muris, Jean W M and de Wit, Niek and Brouwers, Jacobus R B J and van Hee, Koen and Clemens, Cees H M and Haarhuis, Bertram J T and Witteman, Ben J M and Masclee, Ad A M and Keszthelyi, Daniel},
title = {Tailored Treatment of Functional Dyspepsia With Nortriptyline: A Multicenter, Double-Blind, Placebo-Controlled Trial},
journal = {Clinical Gastroenterology and Hepatology},
year = {2026},
volume = {24},
number = {8},
pages = {2273--2285},
doi = {10.1016/j.cgh.2026.01.013}
}
EUVIMED